Rani Therapeutics Pill Platform Accepted Into FDA Program

Rani Therapeutics has secured acceptance into the U.S. Food and Drug Administration's Emerging Technology Program for its RaniPill Capsule platform, providing early regulatory engagement to advance oral biologics delivery.

"Our acceptance into the FDA’s Emerging Technology Program reflects the Agency’s recognition of the RaniPill platform as a novel and innovative approach to the oral delivery of biologics," said Talat Imran, Chief Executive Officer of Rani Therapeutics, in a statement regarding the announcement.

Early Regulatory Engagement and Technical Collaboration

The program acceptance gives Rani Therapeutics direct access to the FDA's Emerging Technology Team. Through this channel, the company can coordinate pre-submission meetings and potential site visits to resolve technical and manufacturing considerations for the oral drug delivery system.

The Emerging Technology Program is designed to facilitate the adoption of innovative manufacturing and design approaches before products reach formal regulatory review stages. For Rani Therapeutics, the engagement offers a structured pathway to address regulatory hurdles associated with replacing traditional biologic injections with an oral capsule format.

Market Valuation and Trading Data

In public markets, Rani Therapeutics Holdings Inc (NASDAQ: RANI) traded at $0.80, rising 0.88% from its previous close of $0.79, according to Finnhub market data as of October 9, 2026, at 20:00 UTC.

What Is at Stake in Oral Biologics

Developing reliable oral delivery mechanisms for biologic drugs remains a central challenge in pharmaceutical development because proteins and peptides are typically degraded in the gastrointestinal tract. Platforms like the RaniPill capsule aim to overcome these barriers, though navigating FDA requirements for novel drug-device combinations requires specialized regulatory alignment throughout the pre-clinical and manufacturing phases.